OPEN DISCUSSION ON PIPELINES OF EXPERIMENTAL TREATMENTS FOR ASTHMA, ALLERGY/RHINITIS, COPD, MULTIMORBIDITY: PANEL DISCUSSION OF RD DIRECTORS OF THE MAIN RESPIRATORY PHARMA INDUSTRIES
Conductors Leonardo M. Fabbri, Pierluigi Paggiaro, Alberto Papi and Giovanni Passalacqua
Introduzione
Mark Parry-Billings
Head of Corporate Drug Development
Chiesi Farmaceutici
Carmen Stabile
Respiratory Medical Lead
GlaxoSmithKline Spa – Pharmaceuticals
Andrea Rizzi
Medical Director Respiratory & Allergy and Diabetes
Ilaria Barisone
Clinical Research Medical Advisor
Novartis Italia
Devis Moretti
Medical Lead Immunology
Sanofi Genzyme
Berta Juliá de Páramo
Regional Director Medical Affairs (EUCAN)
Respiratory, MSD
Najy Alsayed
Global Therapeutic Area Head – Infectious Diseases
Menarini Group
Rita De Santis
Head Biotechnology Research and Development
Alfasigma
Maria Belvisi
SVP Research and Early Development, Respiratory & Immunology, BioPharmaceuticals R&D
AstraZeneca
Discussione